Salt Lake City, Utah, May 25, 2016 – The Board of Directors of Fresh Medical Laboratories Inc., doing business as ProLungdx, today announced the appointment of Dr. John C. Ruckdeschel, M.D. to serve as a Director on the Company’s Board of Directors. Dr. Ruckdeschel is a renowned oncologist with a career-long focus on thoracic malignancies and lung cancer. Dr. Ruckdeschel formerly served as the Medical Director of Clinical Oncology at Intermountain Healthcare in Salt Lake City, Utah, the CEO of Moffitt Cancer Center and is a current member of the Medical Advisory Board of Prolungdx.
“ProLungdx will benefit immensely from the experience Dr. Ruckdeschel offers,” said Steven Eror, President and CEO of ProLungdx. “We are pleased to expand his involvement to our Board of Directors, and we are confident his expertise will help bring our novel technology to those who need it most.”
Dr. Ruckdeschel received his B.S. degree in Biology from Rensselaer Polytechnic Institute and his MD from Albany Medical College in New York. He trained as an intern at John Hopkins Medical Center, fulfilled a residency at Boston’s Beth Israel Hospital and completed a fellowship at the National Cancer Institute in Washington D.C. He is a fellow of the American College of Physicians as well as the American College of Chest Physicians. Dr. Ruckdeschel is also a well accomplished writer and presenter. He has written and co-written more than 350 publications, book chapters and abstracts and has given more than 250 invited presentations.
Dr. Ruckdeschel served on the staff at Albany Medical College for a decade beginning in 1991, before he assumed the role of CEO and Director of the Moffitt Cancer Center in Tampa, FL. In 2001, he became CEO and Director of Karmanos Cancer Institute in Detroit, MI and in 2009 joined the Nevada Cancer Institute, where he worked until 2011 when he joined Intermountain Healthcare. A reputation for effective management and success follows Dr. Ruckdeschel, as he has led significant growth and reached milestones or certifications in all his appointments.
ProLungdx also announces the resignation of Dennis Tulane from the Board of Directors for personal reasons.
ProLungdx is a privately held, US-based medical technology company that develops, manufactures and sells non-invasive medical technology to aid in the early detection and diagnosis of lung cancer. The EPN Scan is approved for sale in the European Economic Area and is for investigational use only in the US.
For more information, contact:
C. Lindsay McSweeney